Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph not_applicable
1
33%
Ph phase_2
2
67%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Terminated(1)

Detailed Status

Not yet recruiting1
Terminated1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

not_yet_recruiting133%
terminated133%
enrolling_by_invitation133%

Recent Activity

0 active trials
Showing 3 of 3
enrolling_by_invitationnot_applicable

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

NCT07102979
not_yet_recruitingphase_2

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

NCT06842472
terminatedphase_2

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

NCT00550862

Clinical Trials (3)

Showing 3 of 3 trials
NCT07102979Not Applicable

Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response

Enrolling By Invitation
NCT06842472Phase 2

PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer

Not Yet Recruiting
NCT00550862Phase 2

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3